Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Jan;31(1):317-323.
doi: 10.1007/s00464-016-4974-y. Epub 2016 Jun 10.

Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy in super obese patients

Adam C Celio  1 , Qiang Wu  2 , Kevin R Kasten  1 , Mark L Manwaring  1 , Walter J Pories  1 , Konstantinos Spaniolas  3
Affiliations
Comparative Study

Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy in super obese patients

Adam C Celio et al. Surg Endosc. 2017 Jan.

Abstract

Background: The disproportionate increase in the super obese (SO) is a hidden component of the current obesity pandemic. Data on the safety and efficacy of bariatric procedures in this specific patient population are limited. Our aim is to assess the comparative effectiveness of the two most common bariatric procedures in the SO.

Methods: Using the Bariatric Outcomes Longitudinal Database from 2007 to 2012, we compared SO patients (BMI ≥ 50) undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). Stepwise logistic regression modeling was used to calculate a propensity score to adjust for patient demographics and comorbidities.

Results: We identified 50,987 SO patients who underwent RYGB (N = 42,119) or SG (N = 8868). There was no difference in adjusted overall 30-day complication rate comparing RYGB and SG patients (11.5 vs. 11.1 %, p = 0.250). RYGB patients had higher adjusted rates of 30-day mortality (0.3 vs. 0.2 %, p = 0.042), reoperation (4.0 vs. 2.4 %, p < 0.001), and readmission (6.9 vs. 5.5 %, p < 0.001) compared to SG patients. The percent of total weight loss (%TWL) was significantly higher for RYGB patients compared to SG at 3 months (14.1 vs. 13.1 %, p < 0.001), 6 months (25.2 vs. 22.4 %, p < 0.001), and 12 months (34.5 vs. 29.7 %, p < 0.001). RYGB patients had increased resolution of all measured comorbidities: diabetes mellitus (61.6 vs. 50.8 %, p < 0.001), hypertension (43.1 vs. 34.5 %, p < 0.001), gastroesophageal reflux disease (53.9 vs. 32.5 %, p < 0.001), hyperlipidemia (39.7 vs. 32.5 %, p < 0.001), and obstructive sleep apnea (42.8 vs. 40.6 %, p = 0.058) at 12 months compared to SG patients.

Conclusions: There are significant differences in comorbidity improvement and resolution as well as weight loss between RYGB and SG in the SO population. There was no difference in overall 30-day complications, but more RYGB patients required readmission and reoperation. However, RYGB was considerably more effective in controlling obesity-related comorbidities. Our results favor performance of RYGB in SO patients of appropriate risk.

Keywords: BOLD; Bariatric surgery; Gastric bypass; Sleeve gastrectomy; Super obese.

PubMed Disclaimer

References

    1. J Gastrointest Surg. 2010 Feb;14(2):211-20 - PubMed
    1. Arch Surg. 2009 Apr;144(4):312-8; discussion 318 - PubMed
    1. Surg Endosc. 2016 Jun;30(6):2505-11 - PubMed
    1. Obes Surg. 2016 Feb;26(2):429-42 - PubMed
    1. Obes Res. 2004 Dec;12(12):1936-43 - PubMed

Publication types

LinkOut - more resources